Novo Nordisk inks pact for discovery of 'molecular glues' in deal worth as much as $1.46B
Novo Nordisk has inked an up to $1.46 billion deal with the biotech Neomorph to develop “molecular glues,” a field that’s seeing a flurry of drugmaker and venture capital interest.
The deal comes with an undisclosed upfront payment. Neomorph is a Deerfield-backed biotech that launched in 2020 with a focus on “molecular glue” degraders. The glues link proteins together in ways that don’t require binding pockets, potentially opening the door to targets once considered “undruggable.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
